Article Text


Case based discussion
Pulmonary hypertension with warm hands
  1. Liza Botros,
  2. Jurjan Aman,
  3. Harm Jan Bogaard,
  4. Anton Vonk Noordegraaf
  1. Department of Pulmonary Medicine, VU University Medical Centre, Amsterdam, The Netherlands
  1. Correspondence to Professor Dr Anton Vonk Noordegraaf, Department of Pulmonary Medicine, VU University Medical Centre, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands; a.vonk{at}

Statistics from

A 19-year-old woman of Moroccan descent presented with severe dyspnoea on exertion. She had difficulty walking stairs (New York Heart Association functional class 3) and accompanying symptoms included fatigue, palpitations and near collapse. She had no cough or wheezing, but mentioned severe and continuous menstrual bleeds since menarche without use of contraceptives. Her medical history included long-standing complaints of fainting, abdominal pains and chest pain, without a clear diagnosis. The family history included hypercholesterolaemia and venous thromboembolic disease (VTE). In fact, 1 year prior to this presentation, the patient was diagnosed with PE herself. Other than a temporary mild polycythaemia (haemoglobin concentration of 16 g/dL) no risk factors for VTE had been discovered at that time.

Physical examination showed a thin woman with a body mass index of 17 kg/m2 (height 161 cm and weight 44 kg). Her blood pressure was 82/51 mm Hg, while her extremities appeared warm. Her heart rate was 91 bpm, the respiratory rate 16/min and oxygen saturation (SpO2) 98%. Heart and lungs appeared normal, but abdominal examination revealed overt hepatosplenomegaly. There were no signs of peripheral oedema, venous thrombosis or clubbing.

Routine blood chemistry showed a haemoglobin level of 16.0 g/dL, haematocrit 57%, a mean corpuscular volume of 72, reticulocyte index 18% together with a serum iron of 6.1 μmol/L and a ferritin of 7 μg/L, suggestive for anaemia secondary to severe iron deficiency, most likely due to hypermenorrhoea. The N-terminal pro brain natriuretic peptide level was elevated to 196 pg/mL. Thrombocytes, white blood cells, kidney function, liver enzymes and thyroid stimulating hormone were all within reference values (see online supplementary table S3). No abnormalities were noted on the chest radiograph; however, a transthoracic echocardiogram showed mild right ventricular (RV) dilatation and dysfunction, a tricuspid annular plane systolic excursion of 23 mm, an estimated RV systolic pressure of 57 mm Hg and right atrial pressure of 5 mm Hg. Furthermore, there was no evidence of paradoxical septal motion. Cardiac magnetic imaging (CMR) was performed which confirmed mild RV dysfunction with an RV ejection fraction of 47% (see online supplementary table S1). The RV appeared mildly dilated and hypertrophic, whereas no signs of valvular abnormalities or intracardiac shunts were noted. This pointed to a pulmonary cause of her RV dysfunction. Spirometry showed a total lung capacity of 3.97 L (4.84 L; 82%), residual volume of 1.08 L (1.31 L; 82%), FVC of 2.65 L (3.59 L; 74%) and a FEV1 of 1.75 L (3.13 L; 56%). Carbon monoxide diffusion capacity (DLCO) was 97.64 μmol/s/kPa (60%) and 6 min walking distance was 370 m with no drop in SpO2. Because of the suspicion of pulmonary hypertension (PH), a right heart catheterisation (RHC) was performed which confirmed PH with an elevated mean pulmonary artery pressure of 56 mm Hg, pulmonary arterial wedge pressure (PAWP) of 16 mm Hg with a moderately elevated pulmonary vascular resistance (PVR) 492 dyn·s/cm5 and decreased systemic vascular resistance (SVR) 742 dyn·s/cm5 (see online supplementary table S2).

Pulmonologist 1: The differential diagnosis of PH is extensive. Causes for pulmonary arterial hypertension (PAH, WHO group 1) such as drugs, anorexins and toxins as well as portal hypertension were excluded. Although left heart conditions such as congenital cardiac defects and valve abnormalities were excluded by CMR, the PAWP was elevated which makes PH due to left disease still a possibility (WHO group 2). The DLCO was reduced and spirometry appeared abnormal, although the latter is probably a consequence of Caucasian reference values. The absence of abnormalities on chest imaging made chronic lung disease-related PH (WHO group 3) unlikely but additional imaging is needed. Given the history of PE, chronic thromboembolic pulmonary hypertension (CTEPH, WHO group 4) was clearly suspected and should be investigated by ventilation/perfusion scintigraphy (V/Q scan). Finally, given the presence of hepatosplenomegaly, WHO group 5 PH (multifactorial mechanisms) is still a possibility although no additional findings point to this direction.

A V/Q scan and CT angiography showed no perfusion defects besides in the left lower lobe due to residual thrombi. There was no evidence of parenchymal lung disease. A diagnosis of inoperable CTEPH was made and the patient was started on treatment with bosentan (125 mg twice daily), tadalafil (40 mg once daily; off-label use) and oral anticoagulants as standard CTEPH treatment. After 1 year on treatment, there was no improvement in exercise tolerance and the fatigue was unaltered. A repeated RHC showed a cardiac output of 13.0 L/min, a PVR of 176 dyn·s/cm5, whereas the SVR was further decreased to 367 dyn·s/cm5. The PAWP remained elevated (see online supplementary table S2). Subsequently, the patient requested a second opinion in our PH expert centre for specialised advanced knowledge on all types of patients with PH.

Pulmonologist 2: A diagnosis of CTEPH may seem reasonable in a patient with PH, a prior VTE and perfusion defects, but in this patient the diagnosis can be challenged. First, it seems difficult to explain the severity of her symptoms and haemodynamics by the minor perfusion defects seen on the V/Q scan, even though firm correlations between clot load and haemodynamics have never been established in CTEPH. Second, a diagnosis of CTEPH requires the presence of perfusion defects in the context of precapillary PH. The haemodynamic profile of this patient was remarkable and inconsistent with a diagnosis of CTEPH, given the supranormal cardiac output and, probably due to a hyperdynamic state, elevated PAWP and low SVR. This combination of findings is highly unusual in most forms of PH, where a low cardiac output is usually associated with a high SVR. Exceptions to this rule are PH related to vascular shunts and chronic liver disease, but no signs or symptoms are pointing towards these conditions. Initiation of tadalafil and an endothelin receptor antagonist resulted in a further increase in cardiac output and decrease in SVR, explaining her warm extremities and aggravating her tendency for collapse. A combination of polycythaemia, hepatosplenomegaly and PH is also found in people living at high altitude. Chronic hypoxia leads to upregulated erythropoietin (EPO) levels and pulmonary vasoconstriction resulting in PH. In fact, blood chemistry revealed an EPO level that was dramatically elevated (see online supplementary table S3). Yet, these EPO levels were found at normoxia. Our patient therefore suffered from secondary erythrocytosis in normoxia. For this reason, routine DNA testing on causes of secondary erythrocytosis was performed.

Medical geneticist: This patient appeared homozygous for a 162G>C mutation in exon 1 leading to an amino acid substitution in the Von Hippel-Lindau (VHL) gene. Her parents, being first cousins, were heterozygous for this mutation. There were no mutations found in the JAK2, prolylhydroxylase-2 (EGLN1/PHD2) and hypoxia inducible factor-2α (HIF2α) genes. Mutations in the VHL gene may impair the degradation of HIFα as seen in patients with Chuvash polycythaemia (CP). CP is a rare autosomal recessive disorder first described in the Volga river region in Russia in the 1970s.1 Patients with CP primarily present with thrombosis and vascular abnormalities combined with notable low blood pressures at young age.1 ,2 The polycythaemia can be explained by the dysregulated oxygen-sensing mechanisms present in normoxia, consequently resulting in transcription of hypoxia-induced genes such as EPO.3 In addition, HIFα regulates several genes involved in vasomotor tone such as endothelin-1, α1B-adrenergic receptor and endothelial nitric oxide which could give rise to the development of PH4 (figure 1). Patients with CP also have an increased risk of mortality because of an increased incidence of cerebral vascular events,2 which risk could be aggravated by the development of PH.

Figure 1

Protein Von Hippel-Lindau (pVHL) regulates hypoxia inducible factor-α (HIFα)-dependent gene transcription. Under normoxic conditions, prolyl hydroxylase (PHD) hydroxylates HIFα in the presence of iron. pVHL recognises hydroxylated HIFα leading to ubiquitination and degradation in the proteasome. In hypoxia, HIFα is not hydroxylated and therefore not recognised for degradation, resulting in transcription of HIFα-dependent genes. When pVHL is mutated, HIFα is hydroxylated but not degraded, leading to accumulation of HIFα. As a result, HIFα and hypoxia-dependent genes are constantly transcribed in normoxia. EPO, erythropoietin; iNO synthase, inducible nitric-oxide synthase; LDH, lactate dehydroxygenase; VEGF, vascular endothelial growth factor.

Resident: In classic VHL tumour predisposition syndrome, heterozygous germ line mutations of VHL are associated with the development of tumours such as renal clear cell carcinoma and vascular tumours.5 Does she have an increased risk for developing malignancies as well?

Medical geneticist: None of the studied CP carriers with an Arg200Trp substitution had any VHL syndrome-associated tumours.2 This could indicate an absence of predisposition to develop tumours but this has to be confirmed by longitudinal studies. Above that, the mutation found in our patient is located at a different site of the gene and therefore no prognosis on predisposition of cancer can be provided.

Pulmonologist 1: The management of PH with a high cardiac output and low SVR, as seen in patients with CP, is complex. Conventional management of PH with pulmonary vasodilators may be started, although this increases the hyperdynamic circulatory state and lowers SVR as seen in this patient. Therefore, PAH-specific therapy was reduced. Patients with VHL-induced PH should be monitored carefully when PAH-specific therapy is initiated. Venesection is a common therapy for polycythaemia and prevents thrombosis, but may also result in iron deficiency. The beneficial effects of venesection in patients with CP are not evident.2 Previous research has even shown that iron depletion increases pulmonary artery pressures,6 partially because the function of HIF proteins is iron dependent.4 The lack of evidence in this field urges further investigation into the role of HIFα and iron status in the development of this type PH specifically, and may yield insights into the pathophysiology of PAH in general.

In conclusion, we present a patient, in whom a rare mutation in the VHL gene leads to a common phenotype of PH with high cardiac output. Constant transcription of HIFα-regulated genes increases EPO plasma concentration and pulmonary vasomotor tone, leading to secondary erythrocytosis and PH, respectively. This case illustrates the importance of careful assessment and monitoring, and the value of PH expert centres, in the evaluation of patients with unexplained PH. Initiation of PAH-specific therapy may aggravate the hyperdynamic circulatory state, and management of these patients should aim for an equilibrium between severe polycythaemia with hyperviscosity and thrombotic risks, and monitoring elevated pulmonary artery pressures with low SVR.


View Abstract


  • Twitter Follow Anton Vonk Noordegraaf @Anton Vonk Noordegraaf

  • Contributors AVN had the idea for the article. LB wrote the first draft of the article. All authors contributed to the final version of the article.

  • Funding JA was funded by the Dutch Heart Foundation (Grant# 2014T064).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.